Gyre Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)3.55 Intrinsic Value $8.96median of 2 methodsbased on filings through 30 Jun 2026 Market Price $7.00Price as of 1 Oct 2026 UndervaluedIntrinsic value is 28% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $742.2M Enterprise Value $698.9M Shares Outstanding 111.8M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Gyre Therapeutics is transitioning into a fully integrated, multi-national biopharmaceutical leader following its strategic acquisition of Cullgen Inc. in May 2026. The company's investment thesis is anchored by a robust commercial foundation in China (led by ETUARY and the newly launched Etorel) and a highly promising late-stage asset, F351 (hydronidone), which has its NDA accepted and under priority review by China's NMPA for CHB-induced liver fibrosis. Furthermore, the Cullgen merger expands Gyre's pipeline into high-growth targeted protein degradation (TPD) and degrader-antibody conjugates (DACs) across oncology and inflammatory diseases, offering significant long-term upside. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$18.00 Mean target$18.67 High · most bullish analyst$20.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $10.0020% China's NMPA delays or issues a complete response letter (CRL) for F351's NDA, severely impacting near-term growth expectations. Clinical trials for F351 in the U.S. or Cullgen's early-stage degrader assets face safety or efficacy hurdles, leading to high cash burn and dilutive financing rounds. Base CaseCentral scenario $17.0050% F351 achieves conditional approval in China by late 2026 or early 2027, establishing a strong second commercial revenue stream alongside ETUARY. The U.S. IND for MASH-associated liver fibrosis is cleared, and Phase 2 trials begin. Cullgen's pipeline advances steadily through early-stage clinical trials with manageable cash burn. Bull CaseUpside scenario $20.0030% F351 receives rapid conditional approval from China's NMPA, capturing a multi-billion dollar market for CHB-induced liver fibrosis. Simultaneously, the U.S. FDA clears the IND for F351 in MASH-associated liver fibrosis, leading to a highly successful Phase 2 trial. Cullgen's protein degrader platform delivers breakthrough clinical data in oncology, driving substantial licensing revenues and partnerships. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |